Celcuity adds ex-Incyte, Celgene CFO David Gryska to board after REVTORPYK launch
The appointment, effective October 1, 2026, follows Celcuity's first FDA approval and the September 30 US launch of REVTORPYK for advanced breast cancer.
Celcuity Inc. announced on October 2, 2026 that its Board of Directors appointed David W. Gryska as a new director, effective October 1, 2026. The Board, acting on the recommendation of its Nominating and Corporate Governance Committee, voted to increase the board from eight members to nine and appointed Gryska to fill the new seat, for a term running through the 2027 Annual Meeting of Stockholders.1 The Board determined that Gryska qualifies as an independent director under Nasdaq listing standards and SEC rules.1 He was also named to the Audit Committee and the Compensation Committee.1
Gryska previously served as Executive Vice President and Chief Financial Officer of Incyte Corporation, Senior Vice President and Chief Financial Officer of Celgene Corporation, and in finance leadership roles at Scios, Inc., and was earlier a partner at Ernst & Young LLP in California.1 Over the past 25 years he has served on the boards of eight public biotechnology companies, currently sits on the board of Definium Therapeutics, and previously served on the boards of Seagen Inc. for more than 15 years, Forte Biosciences, Aerie Pharmaceuticals, and GW Pharmaceuticals.1
CEO Brian Sullivan tied the appointment to the company's commercial transition, saying it comes "on the heels of our first FDA approval for REVTORPYK,"1 as Celcuity moves into a commercial-stage company. Gryska said he was joining at a moment the company described as a new chapter following the approval and launch of REVTORPYK in advanced breast cancer, and said he looks forward to supporting work to advance gedatolisib in additional solid tumor indications.
Gryska will receive pro-rated compensation under Celcuity's non-employee director program, which currently provides a $70,000 annual cash retainer and a $100,000 annual equity award, and the company granted him 893 restricted stock units under its 2026 Stock Incentive Plan, vesting at the earlier of the 2027 Annual Meeting or April 30, 2027.1
REVTORPYK became commercially available in the US on September 30, 2026 for HR+/HER2- advanced breast cancer patients without a PIK3CA mutation, following FDA approval on July 14, 2026, and Celcuity has said it submitted a supplemental New Drug Application in August seeking approval for patients with PIK3CA-mutated disease.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.